Nuage Therapeutics, a spin-off of IRB Barcelona and ICREA, has raised €12M in Seed Financing to advance its lead programme targeting intrinsically disordered proteins (IDPs). Sofinnova Partners and Asabys head the investment, aiming to develop treatments for castration-resistant prostate cancer and other untreatable conditions. Founded by Drs. Xavier Salvatella, Mateusz Biesaga, Denes Hnisz, and Judit Anido, Nuage's pioneering drug discovery platform leverages biomolecular condensation.
Dr. Judit Anido, CEO of Nuage, emphasises the significance of targeting IDPs, historically overlooked but crucial in numerous diseases. Sofinnova Partners expresses excitement over their first investment in Spain, highlighting Nuage's innovative approach in cancer therapeutics. Asabys, a long-time supporter, underscores Nuage's potential in revolutionising cancer treatments, highlighting breakthrough solutions for challenging indications.
For more information: https://www.irbbarcelona.org/en/news/institutional/nuage-therapeutics-raises-eu12m-seed-financing-led-sofinnova-partners-and-asabys
